Collegium Pharmaceutical Current Ratio Growth & History (COLL)
Collegium Pharmaceutical's current ratio was 1.57 for fiscal 2025.
View full Collegium Pharmaceutical company overviewCollegium Pharmaceutical annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.57 | 0.62 | +66.01% |
| 2024 | 2024-12-31 | 0.95 | −0.23 | −19.38% |
| 2023 | 2023-12-31 | 1.17 | 0.21 | +21.24% |
| 2022 | 2022-12-31 | 0.97 | −0.16 | −14.21% |
| 2021 | 2021-12-31 | 1.13 | −0.03 | −2.74% |
| 2020 | 2020-12-31 | 1.16 | −0.11 | −8.43% |
| 2019 | 2019-12-31 | 1.27 | 0.01 | +0.92% |
| 2018 | 2018-12-31 | 1.26 | −2.98 | −70.38% |
| 2017 | 2017-12-31 | 4.24 | −1.96 | −31.57% |
| 2016 | 2016-12-31 | 6.20 | −5.29 | −46.08% |
| 2015 | 2015-12-31 | 11.49 | 11.06 | +2562.16% |
| 2014 | 2014-12-31 | 0.43 | — | — |
Collegium Pharmaceutical quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.03 | −0.15 | −12.80% |
| Q1 2026 | 2026-03-31 | 1.71 | 0.63 | +58.16% |
| Q4 2025 | 2025-12-31 | 1.57 | 0.62 | +66.01% |
| Q3 2025 | 2025-09-30 | 1.36 | 0.39 | +40.30% |
| Q2 2025 | 2025-06-30 | 1.18 | 0.08 | +6.98% |
| Q1 2025 | 2025-03-31 | 1.08 | −0.12 | −10.27% |
| Q4 2024 | 2024-12-31 | 0.95 | −0.23 | −19.38% |
| Q3 2024 | 2024-09-30 | 0.97 | −0.19 | −16.43% |
| Q2 2024 | 2024-06-30 | 1.11 | −0.13 | −10.53% |
| Q1 2024 | 2024-03-31 | 1.21 | 0.00 | +0.04% |
| Q4 2023 | 2023-12-31 | 1.17 | 0.21 | +21.24% |
| Q3 2023 | 2023-09-30 | 1.16 | 0.18 | +18.25% |
| Q2 2023 | 2023-06-30 | 1.24 | 0.25 | +25.10% |
| Q1 2023 | 2023-03-31 | 1.21 | 0.23 | +24.04% |
| Q4 2022 | 2022-12-31 | 0.97 | −0.16 | −14.21% |
| Q3 2022 | 2022-09-30 | 0.98 | −0.37 | −27.61% |
| Q2 2022 | 2022-06-30 | 0.99 | −0.42 | −29.70% |
| Q1 2022 | 2022-03-31 | 0.97 | −0.31 | −24.39% |
| Q4 2021 | 2021-12-31 | 1.13 | −0.03 | −2.74% |
| Q3 2021 | 2021-09-30 | 1.35 | 0.27 | +24.90% |
| Q2 2021 | 2021-06-30 | 1.40 | 0.41 | +41.15% |
| Q1 2021 | 2021-03-31 | 1.29 | 0.37 | +40.65% |
| Q4 2020 | 2020-12-31 | 1.16 | −0.11 | −8.43% |
| Q3 2020 | 2020-09-30 | 1.08 | −0.16 | −12.78% |
| Q2 2020 | 2020-06-30 | 0.99 | −0.25 | −20.16% |
| Q1 2020 | 2020-03-31 | 0.92 | −0.32 | −26.07% |
| Q4 2019 | 2019-12-31 | 1.27 | 0.01 | +0.92% |
| Q3 2019 | 2019-09-30 | 1.24 | 0.46 | +58.65% |
| Q2 2019 | 2019-06-30 | 1.25 | 0.43 | +52.49% |
| Q1 2019 | 2019-03-31 | 1.24 | 0.41 | +49.14% |
| Q4 2018 | 2018-12-31 | 1.26 | −2.98 | −70.38% |
| Q3 2018 | 2018-09-30 | 0.78 | −3.72 | −82.65% |
| Q2 2018 | 2018-06-30 | 0.82 | −3.41 | −80.65% |
| Q1 2018 | 2018-03-31 | 0.83 | −4.73 | −85.08% |
| Q4 2017 | 2017-12-31 | 4.24 | −1.96 | −31.57% |
| Q3 2017 | 2017-09-30 | 4.50 | 0.21 | +4.91% |
| Q2 2017 | 2017-06-30 | 4.22 | −2.17 | −33.99% |
| Q1 2017 | 2017-03-31 | 5.56 | −6.68 | −54.58% |
| Q4 2016 | 2016-12-31 | 6.20 | −5.29 | −46.08% |
| Q3 2016 | 2016-09-30 | 4.29 | −8.07 | −65.27% |
| Q2 2016 | 2016-06-30 | 6.40 | −11.96 | −65.15% |
| Q1 2016 | 2016-03-31 | 12.25 | 5.27 | +75.41% |
| Q4 2015 | 2015-12-31 | 11.49 | 11.06 | +2562.16% |
| Q3 2015 | 2015-09-30 | 12.36 | — | — |
| Q2 2015 | 2015-06-30 | 18.36 | — | — |
| Q1 2015 | 2015-03-31 | 6.98 | — | — |
| Q4 2014 | 2014-12-31 | 0.43 | — | — |
Collegium Pharmaceutical current ratio trends
Over the last five fiscal years, Collegium Pharmaceutical's current ratio increased from 1.16 to 1.57, a change of 0.41. The latest reported quarter, Q2 2026, shows 1.03.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Collegium Pharmaceutical source filings ↗